title: Results of the application of intraoperative mitomycin C in dacryocystorhinostomy.
abstract: OBJECTIVE
  Dacryocystorhinostomy (DCR) is widely accepted as the procedure of choice for surgical correction of lacrimal drainage system obstruction distal to common canaliculus in adulthood. The success rate of DCR has been reported to be from 63% to 99%. DCR failure has been attributed to membranous occlusion of the rhinostomy site caused by soft tissue scarring. More recently, use of mitomycin C (MMC) has been described in lacrimal drainage surgery. The beneficial effect of MMC as a surgical adjunct is thought to be related to its potent inhibition of fibroblast proliferation.
  
  
  METHODS
  To improve the success rate of DCR, the authors used MMC as an adjunct to surgery in 130 patients with nasolacrimal duct obstruction undergoing lacrimal surgery. They were assigned randomly into a MMC DCR group and a regular DCR group (control group).
  
  
  RESULTS
  The mean age of the MMC group was 40+/-15 years and that of the control group was 42+/-16 years. The standard surgical techniques of an external DCR were used in all patients of both groups. Patients were followed for 6 months. The authors evaluated the patients with subjective symptoms (improvement in tearing) and objective findings such as the height of tear meniscus, fluorescein dye test, and patency at the time of irrigation. There was no significant difference in the age between the two groups (p=1.00). Six patients in the mitomycin group were symptomatic after 6 months' follow-up; probe and irrigation showed non-patency of lacrimal system. The success rate in the MMC group was therefore 90.5% (59/65), and in the conventional group it was 92.4% (60/65). No significant difference between the two groups was present (p=0.75).
  
  
  CONCLUSIONS
  The authors conclude that the use of intraoperative MMC in DCR surgery does not change the success rate of this procedure.
authors.affiliation: Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz - Iran.
authors.forename: M H
authors.initials: MH
authors.lastname: Roozitalab
authors.forename: M
authors.initials: M
authors.lastname: Amirahmadi
authors.forename: M R
authors.initials: MR
authors.lastname: Namazi
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003608:Dacryocystorhinostomy / Q000379:methods*; D005260:Female; D005347:Fibroblasts / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D007430:Intraoperative Care; D007767:Lacrimal Duct Obstruction / Q000188:drug therapy*; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use*; D009301:Nasolacrimal Duct / Q000187:drug effects / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin